金寶通(00320.HK)中期純利210.6萬港元 同比減少87.38%
格隆匯 11 月 27日丨金寶通(00320.HK)發佈公告,截至2020年9月30日止6個月,公司收益15億港元,同比減少6.21%;公司擁有人應占溢利210.6萬港元,同比減少87.38%;每股盈利0.25港仙。
期間內,疫情導致全球經濟下滑,金寶通的業務表現亦因而受壓。主要由於2019冠狀病毒病引發封城等措施,客户供應鏈出現中斷情況,收入同比小幅下降。
此外,所銷售的產品組合亦受主要市場封城影響,加上為未來着想重組生產成架構所錄得的一次性人員下崗開支,毛利率同比小幅下降2.5個百分點。受益於所執行的多項成控制措施取得一定成果,期間銷售及分銷開支和行政開支均錄得同比減幅。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.